The Molecular Mechanism of Cheng's Juanbi Decoction in Regulating the PI3K/Akt/mTOR Pathway for Rheumatoid
Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v6i1.3669
Abstract
Cheng's Juanbi Decoction (CJD) is a traditional Chinese medicinal formula widely used in the treatment of rheumatoid arthritis (RA). Recent studies have suggested that the therapeutic effects of CJD are closely linked to the regulation of several key signaling pathways, particularly the PI3K/Akt/mTOR pathway. This pathway plays a crucial role in cellular processes such as inflammation, immune response, and cartilage degradation, all of which are central to the pathogenesis of RA. The molecular mechanism by which CJD exerts its effects on this pathway remains poorly understood. This review aims to explore the molecular interactions of CJD components with the PI3K/Akt/mTOR signaling pathway in the context of RA. By analyzing recent research and clinical studies, we highlight how the active compounds in CJD, including flavonoids, alkaloids, and polysaccharides, modulate the expression of key proteins involved in this pathway. Specifically, CJD has been shown to downregulate the overactivation of PI3K, Akt, and mTOR, thereby reducing inflammatory responses, promoting cell survival, and inhibiting excessive synovial cell proliferation and cartilage destruction. Moreover, we discuss the potential of CJD as an adjunct therapy to conventional RA treatments, with emphasis on its synergistic effects and safety profile. In conclusion, this review provides a comprehensive overview of the molecular mechanisms underlying the action of Cheng's Juanbi Decoction in RA, offering new insights into its therapeutic potential and clinical applications.
Keywords
Cheng's Juanbi Decoction, rheumatoid arthritis, PI3K/Akt/mTOR pathway, molecular mechanism, traditional Chinese medicine (TCM)
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[2] Huang RZ, Zheng J, Liu FL, et al. A novel autophagy-related marker for improved differential diagnosis of rheumatoid arthritis and osteoarthritis [J]. Front Genet, 2021.
[3] Zhao JN, Jiang P, Guo SC, et al. Apoptosis, autophagy, NETosis, necroptosis, and pyroptosis mediated programmed cell death as targets for innovative therapy in rheumatoid arthritis [J]. Front Immunol, 2021.
[4] Hao Z, Liu Y. IL-38 and IL-36 target autophagy for regulating synoviocyte proliferation, migration, and invasion in rheumatoid arthritis [J]. Dis Markers, 2021.
[5] Hong Lan. Mechanism of Sanbaibang inhibiting MH7A cell proliferation based on PI3K/AKT/mTOR autophagy signaling pathway [D]. Hubei Minzu University, 2022.
[6] Sun H, Wang ZY, Yakisich JS. Natural products targeting autophagy via the PI3K/Akt/mTOR pathway as anticancer agents [J]. Anticancer Agents Med Chem, 2013.
[7] Wang QY, Yao XM, Xu H, et al. Jinwu Jiangu Capsule affects synovial cells in rheumatoid arthritis through PI3K/Akt/mTOR signaling pathway [J]. Acta Biochim Pol, 2021.
[8] Jiang Hui, Qin Xiujuan, Wan Lei, et al. Effect of Wuwei Wentong Chubi Capsule on the expressions of autophagy proteins Beclin-1 and LC3-Ⅱ in adjuvant arthritis rats [J]. Chinese Traditional Patent Medicine, 2017.
[9] Hao Feng, Wu Libin, Hu Jun, et al. Effect of moxibustion on PI3K/Akt/mTOR signaling pathway in synovial tissue of foot plantar in rheumatoid arthritis model rats [J]. Chinese Acupuncture & Moxibustion, 2020.
[10] Ma Tai, Sun Guoping, Li Jiabin. Research methods of cell autophagy [J]. Progress in Biochemistry and Biophysics, 2012.
Copyright © 2025 Mu He, Kejia Cao, Chaoyong Li, Yue Cao, Le Ding
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
